Hanaa H Gaballah1, Soha S Zakaria2, Shorouk E Mwafy3, Nahid M Tahoon4, Abla M Ebeid5. 1. Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt. Electronic address: hanaa.hibishy@med.tanta.edu.eg. 2. Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt. 3. Histopathology department, Faculty of medicine, Tanta, Egypt. 4. Physiology Departments, Faculty of Medicine, Tanta University, Tanta, Egypt. 5. Clinical pharmacy Department, Faculty of Pharmacy, AL-Delta University, Gamasa, Egypt.
Abstract
BACKGROUND: The development of complementary treatment strategies that focuses on achieving a balance between adaptive and apoptotic unfolded protein response (UPR), enhancing endoplasmic reticulum (ER) homeostasis, and thus preserving β cell mass and function is particularly warranted. AIM: This study was designed to investigate the effectiveness of the combined treatment by Quercetin (QUE) and Liraglutide (LIRA) in modulating hyperglycemia, insulin-insensitivity, UPR/ER stress markers, apoptosis, oxidative stress and inflammation using a high-fat diet/streptozotocin -induced type 2 diabetic rat model. METHODS: Sixty male albino rats were allocated into five equal groups: normal control, diabetic control, LIRA treated diabetic; QUE treated diabetic and combined treatment diabetic groups. Fasting glucose, insulin, CHOP, macrophage inflammatory protein -1 α (MIP-1α) and Bax, Bcl2 levels were estimated by ELISA; mRNA expression levels of the spliced X-box binding protein 1 (XBP1) were estimated using quantitative real-time RT-PCR, while MDA, advanced oxidation protein products, reduced glutathione levels and protein disulfide isomerase (PDI) activity were evaluated spectrophotometrically. Pancreatic tissues were also subjected to histopathological examination. RESULTS: The combined treatment with both LIRA and QUE causes significant improvements in all the studied parameters; including XBP1 splicing, CHOP, MIP-1α, Bax/Bcl2 ratio, PDI activity, as well as oxidative stress markers as compared to either treatment alone. It also attenuated pancreatic histopathological damage. IN CONCLUSION: Our study nominates this combination to be used in T2DM to achieve adequate glycaemic control and to preserve optimal β cell function.
BACKGROUND: The development of complementary treatment strategies that focuses on achieving a balance between adaptive and apoptotic unfolded protein response (UPR), enhancing endoplasmic reticulum (ER) homeostasis, and thus preserving β cell mass and function is particularly warranted. AIM: This study was designed to investigate the effectiveness of the combined treatment by Quercetin (QUE) and Liraglutide (LIRA) in modulating hyperglycemia, insulin-insensitivity, UPR/ER stress markers, apoptosis, oxidative stress and inflammation using a high-fat diet/streptozotocin -induced type 2 diabeticrat model. METHODS: Sixty male albino rats were allocated into five equal groups: normal control, diabetic control, LIRA treated diabetic; QUE treated diabetic and combined treatment diabetic groups. Fasting glucose, insulin, CHOP, macrophage inflammatory protein -1 α (MIP-1α) and Bax, Bcl2 levels were estimated by ELISA; mRNA expression levels of the spliced X-box binding protein 1 (XBP1) were estimated using quantitative real-time RT-PCR, while MDA, advanced oxidation protein products, reduced glutathione levels and protein disulfide isomerase (PDI) activity were evaluated spectrophotometrically. Pancreatic tissues were also subjected to histopathological examination. RESULTS: The combined treatment with both LIRA and QUE causes significant improvements in all the studied parameters; including XBP1 splicing, CHOP, MIP-1α, Bax/Bcl2 ratio, PDI activity, as well as oxidative stress markers as compared to either treatment alone. It also attenuated pancreatic histopathological damage. IN CONCLUSION: Our study nominates this combination to be used in T2DM to achieve adequate glycaemic control and to preserve optimal β cell function.
Authors: Fahadul Islam; Jannatul Fardous Khadija; Md Rezaul Islam; Sheikh Shohag; Saikat Mitra; Saad Alghamdi; Ahmad O Babalghith; Abdulrahman Theyab; Mohammad Tauhidur Rahman; Aklima Akter; Abdullah Al Mamun; Fahad A Alhumaydhi; Talha Bin Emran Journal: Evid Based Complement Alternat Med Date: 2022-06-21 Impact factor: 2.650
Authors: Graziele Freitas de Bem; Cristiane Aguiar Costa; Izabelle Barcellos Santos; Viviane da Silva Cristino Cordeiro; Lenize Costa Reis Marins de Carvalho; Marcelo Augusto Vieira de Souza; Ricardo de Andrade Soares; Pergentino José da Cunha Sousa; Dayane Teixeira Ognibene; Angela Castro Resende; Roberto Soares de Moura Journal: PLoS One Date: 2018-06-19 Impact factor: 3.240
Authors: Bahare Salehi; Laura Machin; Lianet Monzote; Javad Sharifi-Rad; Shahira M Ezzat; Mohamed A Salem; Rana M Merghany; Nihal M El Mahdy; Ceyda Sibel Kılıç; Oksana Sytar; Mehdi Sharifi-Rad; Farukh Sharopov; Natália Martins; Miquel Martorell; William C Cho Journal: ACS Omega Date: 2020-05-14